Primary graft dysfunction after heart transplantation: a thorn amongst the roses

1.

Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ et al (2017) The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report; focus theme: allograft ischemic time. J Heart Lung Transplant 36(10):1037–1046PubMedCrossRef

2.

Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD et al (2013) The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report—2013; focus theme: age. J Heart Lung Transplant 32(10):951–964PubMedCrossRef

3.

Segovia J, Pulpón LA, Sanmartín M, Tejero C, Serrano S, Burgos R et al (1998) Primary graft failure in heart transplantation: a multivariate analysis. Transplant Proc 30(5):1932PubMedCrossRef

4.

Russo MJ, Iribarne A, Hong KN, Ramlawi B, Chen JM, Takayama H et al (2010) Factors associated with primary graft failure after heart transplantation. Transplantation. 90(4):444–450PubMedCrossRef

5.

Iyer A, Kumarasinghe G, Hicks M, Watson A, Gao L, Doyle A et al (2011) Primary graft failure after heart transplantation. J Transplant 2011:175768PubMedPubMedCentralCrossRef

6.

Kobashigawa J, Zuckermann A, Macdonald P, Leprince P, Esmailian F, Luu M et al (2014) Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant 33(4):327–340PubMedCrossRef

7.

Wernovsky G, Wypij D, Jonas RA, Mayer JE Jr, Hanley FL, Hickey PR et al (1995) Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation. 92(8):2226–2235PubMedCrossRef

8.

Dronavalli VB, Rogers CA, Banner NR (2015) Primary cardiac allograft dysfunction-validation of a clinical definition. Transplantation. 99(9):1919–1925PubMedPubMedCentralCrossRef

9.

D'Alessandro C, Aubert S, Golmard JL, Praschker BL, Luyt CE, Pavie A et al (2010) Extra-corporeal membrane oxygenation temporary support for early graft failure after cardiac transplantation. Eur J Cardiothorac Surg 37(2):343–349PubMed

10.

Oto T, Excell L, Griffiths AP, Levvey BJ, Bailey M, Marasco S et al (2008) Association between primary graft dysfunction among lung, kidney and heart recipients from the same multiorgan donor. Am J Transplant 8(10):2132–2139PubMedCrossRef

11.

Ibrahim M, Hendry P, Masters R, Rubens F, Lam BK, Ruel M et al (2007) Management of acute severe perioperative failure of cardiac allografts: a single-centre experience with a review of the literature. Can J Cardiol 23(5):363–367PubMedPubMedCentralCrossRef

12.

Chew HC, Kumarasinghe G, Iyer A, Hicks M, Gao L, Doyle A et al (2014) Primary graft dysfunction after heart transplantation. Curr Transplant Rep 1(4):257–265CrossRef

13.

Gordon JK, McKinlay J (2012) Physiological changes after brain stem death and management of the heart-beating donor. Contin Educ Anaesth Crit Care Pain 12(5):225–229CrossRef

14.

Dictus C, Vienenkoetter B, Esmaeilzadeh M, Unterberg A, Ahmadi R (2009) Critical care management of potential organ donors: our current standard. Clin Transpl 23(Suppl 21):2–9CrossRef

15.

Shivalkar B, Van Loon J, Wieland W, Tjandra-Maga TB, Borgers M, Plets C et al (1993) Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation. 87(1):230–239PubMedCrossRef

16.

Souter MJ, Eidbo E, Findlay JY, Lebovitz DJ, Moguilevitch M, Neidlinger NA et al (2017) Organ donor management: part 1. Toward a consensus to guide anesthesia services during donation after brain death. Semin Cardiothorac Vasc Anesth 22(2):211–222PubMedCrossRef

17.

Rosendale JD, Kauffman HM, McBride MA, Chabalewski FL, Zaroff JG, Garrity ER et al (2003) Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 75(8):1336–1341PubMedCrossRef

18.

Meers CM, Wauters S, Verbeken E, Scheers H, Vanaudenaerde B, Verleden GM et al (2011) Preemptive therapy with steroids but not macrolides improves gas exchange in caustic-injured donor lungs. J Surg Res 170(1):e141–e1e8PubMedCrossRef

19.

Venkateswaran RV, Patchell VB, Wilson IC, Mascaro JG, Thompson RD, Quinn DW et al (2008) Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg 85(1):278–286PubMedCrossRef

20.

Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB (2004) Care of the potential organ donor. N Engl J Med 351(26):2730–2739PubMedCrossRef

21.

Kumar TKS, Mathis C, Sathanandam S, Zurakowski D, Subramanian S, Allen J et al (2017) Effect of thyroid hormone on cardiac function following orthotopic heart transplantation in piglets. Pediatr Transplant 21(6)

22.

Novitzky D, Mi Z, Collins JF, Cooper DK (2015) Increased procurement of thoracic donor organs after thyroid hormone therapy. Semin Thorac Cardiovasc Surg 27(2):123–132PubMedCrossRef

23.

Schipper DA, Marsh KM, Ferng AS, Duncker DJ, Laman JD, Khalpey Z (2016) The critical role of bioenergetics in donor cardiac allograft preservation. J Cardiovasc Transl Res 9(3):176–183PubMedCrossRef

24.

Belzer FO, Southard JH (1988) Principles of solid-organ preservation by cold storage. Transplantation. 45(4):673–676PubMedCrossRef

25.

Marelli D, Laks H, Fazio D, Moore S, Moriguchi J, Kobashigawa J (2000) The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant 19(5):496–503PubMedCrossRef

26.

Anaya-Prado R, Delgado-Vazquez JA (2008) Scientific basis of organ preservation. Curr Opin Organ Transplant 13(2):129–134PubMedCrossRef

27.

Vigne P, Frelin C, Lazdunski M (1985) The Na+/H+ exchanger in eukaryotic cells: biochemical and pharmacological properties and physiological role. Biochimie. 67(1):129–135PubMedCrossRef

28.

Karmazyn M, Gan XT, Humphreys RA, Yoshida H, Kusumoto K (1999) The myocardial Na(+)-H(+) exchange: structure, regulation, and its role in heart disease. Circ Res 85(9):777–786PubMedCrossRef

29.

Marasco SF, Kras A, Schulberg E, Vale M, Lee GA (2012) Impact of warm ischemia time on survival after heart transplantation. Transplant Proc 44(5):1385–1389PubMedCrossRef

30.

Braunwald E, Kloner RA (1985) Myocardial reperfusion: a double-edged sword? J Clin Invest 76(5):1713–1719PubMedPubMedCentralCrossRef

31.

Morciano G, Bonora M, Campo G, Aquila G, Rizzo P, Giorgi C et al (2017) Mechanistic role of mPTP in ischemia-reperfusion injury. In: Santulli G (ed) Mitochondrial dynamics in cardiovascular medicine. Springer International Publishing, Cham, pp 169–189CrossRef

32.

Penna C, Perrelli MG, Pagliaro P (2013) Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid Redox Signal 18(5):556–599PubMedCrossRef

33.

Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M (2005) Postconditioning inhibits mitochondrial permeability transition. Circulation. 111(2):194–197PubMedCrossRef

34.

Upadhaya S, Madala S, Baniya R, Subedi SK, Saginala K, Bachuwa G (2017) Impact of cyclosporine A use in the prevention of reperfusion injury in acute myocardial infarction: a meta-analysis. Cardiol J 24(1):43–50PubMedCrossRef

35.

Hausenloy D, Wynne A, Duchen M, Yellon D (2004) Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation. 109(14):1714–1717PubMedCrossRef

36.

Birnbaum Y, Hale SL, Kloner RA (1997) Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation 96(5):1641–1646PubMedCrossRef

37.

Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM (1991) Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 84(1):350–356PubMedCrossRef

38.

Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S et al (2013) Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet (London, England) 382(9892):597–604CrossRef

39.

Benstoem C, Stoppe C, Liakopoulos OJ, Ney J, Hasenclever D, Meybohm P et al (2017) Remote ischaemic preconditioning for coronary artery bypass grafting (with or without valve surgery). Cochrane Database Syst Rev 5:Cd011719PubMed

40.

D'Ascenzo F, Cavallero E, Moretti C, Omede P, Sciuto F, Rahman IA et al (2012) Remote ischaemic preconditioning in coronary artery bypass surgery: a meta-analysis. Heart. 98(17):1267–1271PubMedCrossRef

41.

Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S et al (2015) Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med 373(15):1408–1417PubMedCrossRef

42.

Pierce B, Bole I, Patel V, Brown DL. Clinical outcomes of remote ischemic preconditioning prior to cardiac surgery: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2017;6(2)

43.

Meybohm P, Kohlhaas M, Stoppe C, Gruenewald M, Renner J, Bein B, et al. RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) study: myocardial dysfunction, postoperative neurocognitive dysfunction, and 1 year follow-up. J Am Heart Assoc. 2018;7(7)

44.

Kleinbongard P, Neuhauser M, Thielmann M, Kottenberg E, Peters J, Jakob H et al (2016) Confounders of cardioprotection by remote ischemic preconditioning in patients undergoing coronary artery bypass grafting. Cardiology. 133(2):128–133PubMedCrossRef

45.

Konstantinov IE, Li J, Cheung MM, Shimizu M, Stokoe J, Kharbanda RK et al (2005) Remote ischemic preconditioning of the recipient reduces myocardial ischemia-reperfusion injury of the denervated donor heart via a Katp channel-dependent mechanism. Transplantation. 79(12):1691–1695PubMedCrossRef

46.

Nieszner E, Posa I, Kocsis E, Pogatsa G, Preda I, Koltai MZ (2002) Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits. Exp Clin Endocrinol Diabetes 110(5):212–218PubMedCrossRef

47.

Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K et al (2001) Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 38(4):1007–1011PubMedCrossRef

48.

Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT et al (2004) Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia. 47(10):1716–1721PubMedCrossRef

49.

Crisostomo PR, Wang M, Wairiuko GM, Terrell AM, Meldrum DR (2006) Postconditioning in females depends on injury severity. J Surg Res 134(2):342–347PubMedCrossRef

50.

Heinen A, Behmenburg F, Aytulun A, Dierkes M, Zerbin L, Kaisers W et al (2018) The release of cardioprotective humoral factors after remote ischemic preconditioning in humans is age- and sex-dependent. J Transl Med 16(1):112PubMedPubMedCentralCrossRef

51.

Moolman JA, Genade S, Tromp E, Opie LH, Lochner A (1997) Ischaemic preconditioning does not protect hypertrophied myocardium against ischaemia. S Afr Med J = Suid-Afrikaanse tydskrif vir geneeskunde 87(Suppl 3):C151–C156PubMed

52.

Ebrahim Z, Yellon DM, Baxter GF (2007) Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension. Exp Gerontol 42(8):807–814PubMedCrossRef

53.

Bartling B, Friedrich I, Silber RE, Simm A (2003) Ischemic preconditioning is not cardioprotective in senescent human myocardium. Ann Thorac Surg 76(1):105–111PubMedCrossRef

54.

Nichols CG, Lederer WJ (1990) The role of ATP in energy-deprivation contractures in unloaded rat ventricular myocytes. Can J Physiol Pharmacol 68(2):183–194PubMedCrossRef

55.

Schluter KD, Jakob G, Ruiz-Meana M, Garcia-Dorado D, Piper HM (1996) Protection of reoxygenated cardiomyocytes against osmotic fragility by nitric oxide donors. Am J Phys 271(2 Pt 2):H428–H434

56.

Piper HM, Abdallah Y, Schäfer C (2004) The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 61(3):365–371PubMedCrossRef

57.

Inserte J, Garcia-Dorado D, Hernando V, Soler-Soler J (2005) Calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion contributes to cell death after myocardial ischemia. Circ Res 97(5):465–473PubMedCrossRef

58.

Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Agulló L, Cabestrero A (2006) The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia–reperfusion. Cardiovasc Res 70(2):274–285PubMedCrossRef

59.

Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M (2004) Gap junction-mediated spread of cell injury and death during myocardial ischemia-reperfusion. Cardiovasc Res 61(3):386–401PubMedCrossRef

60.

White CW, Messer SJ, Large SR, Conway J, Kim DH, Kutsogiannis DJ et al (2018) Transplantation of hearts donated after circulatory death. Front Cardiovasc Med 5:8PubMedPubMedCentralCrossRef

61.

White CW, Lillico R, Sandha J, Hasanally D, Wang F, Ambrose E et al (2016) Physiologic changes in the heart following cessation of mechanical ventilation in a porcine model of donation after circulatory death: implications for cardiac transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 16(3):783–793CrossRef

62.

Manara AR, Murphy PG, O'Callaghan G (2012) Donation after circulatory death. Br J Anaesth 108(suppl_1):i108–ii21PubMedCrossRef

63.

Page A, Messer S, Large SR (2018) Heart transplantation from donation after circulatory determined death. Ann Cardiothorac Surg 7(1):75–81PubMedPubMedCentralCrossRef

64.

Chan JL, Kobashigawa JA, Aintablian TL, Li Y, Perry PA, Patel JK et al (2017) Vasoplegia after heart transplantation: outcomes at 1 year†. Interact Cardiovasc Thorac Surg 25(2):212–217PubMedCrossRef

65.

Omar S, Zedan A, Nugent K (2015) Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. Am J Med Sci 349(1):80–88PubMedCrossRef

66.

Rylski B, Berchtold-Herz M, Olschewski M, Zeh W, Schlensak C, Siepe M et al (2010) Reducing the ischemic time of donor hearts will decrease morbidity and costs of cardiac transplantations☆. Interact Cardiovasc Thorac Surg 10(6):945–947PubMedCrossRef

67.

Stobierska-Dzierzek B, Awad H, Michler RE (2001) The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 38(4):923–931PubMedCrossRef

68.

Russo MJ, Chen JM, Sorabella RA, Martens TP, Garrido M, Davies RR et al (2007) The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 133(2):554–559PubMedCrossRef

69.

Loebe M, Potapov EV, Hummel M, Weng Y, Bocksch W, Hetzer R (2000) Medium-term results of heart transplantation using older donor organs. J Heart Lung Transplant 19(10):957–963PubMedCrossRef

70.

Lietz K, John R, Mancini DM, Edwards NM (2004) Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list: implications for donor selection criteria. J Am Coll Cardiol 43(9):1553–1561PubMedCrossRef

71.

Blanche C, Kamlot A, Blanche DA, Kearney B, Magliato KE, Czer LSC et al (2002) Heart transplantation with donors fifty years of age and older. J Thorac Cardiovasc Surg 123(4):810–815PubMedCrossRef

72.

Potapov EV, Loebe M, Hubler M, Musci M, Hummel M, Weng Y et al (1999) Medium-term results of heart transplantation using donors over 63 years of age. Transplantation. 68(12):1834–1838PubMedCrossRef

73.

Croome KP, Dan S, Roberto HA, Adams PC, Alan T, Natasha C (2014) Female donor to male recipient gender discordance results in inferior graft survival: a prospective study of 1,042 liver transplants. J Hepatobiliary Pancreat Sci 21(4):269–274PubMedCrossRef

74.

Gratwohl A, Hermans J, Niederwieser D, van Biezen A, van Houwelingen HC, Apperley J et al (2001) Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J 2(6):363–370PubMedCrossRef

75.

Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U et al (2015) Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? Biol Blood Marrow Transplant 21(4):713–719PubMedCrossRef

76.

Yamani MH, Lauer MS, Starling RC, Pothier CE, Tuzcu EM, Ratliff NB et al (2004) Impact of donor spontaneous intracranial hemorrhage on outcome after heart transplantation. Am J Transplant 4(2):257–261PubMedCrossRef

77.

Shanlin RJ, Sole MJ, Rahimifar M, Tator CH, Factor SM (1988) Increased intracranial pressure elicits hypertension, increased sympathetic activity, electrocardiographic abnormalities and myocardial damage in rats. J Am Coll Cardiol 12(3):727–736PubMedCrossRef

78.

Tsai FC, Marelli D, Bresson J, Gjertson D, Kermani R, Patel J et al (2002) Use of hearts transplanted from donors with atraumatic intracranial bleeds. J Heart Lung Transplant 21(6):623–628PubMedCrossRef

79.

Lima B, Rajagopal K, Petersen RP, Shah AS, Soule B, Felker GM et al (2006) Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. Circulation. 114(1 Suppl):I27–I32PubMed

80.

Goland S, Czer LS, Kass RM, Siegel RJ, Mirocha J, De Robertis MA et al (2008) Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J Am Coll Cardiol 51(12):1214–1220PubMedCrossRef

81.

Felker GM, Milano CA, Yager JE, Hernandez AF, Blue L, Higginbotham MB et al (2005) Outcomes with an alternate list strategy for heart transplantation. J Heart Lung Transplant 24(11):1781–1786PubMedCrossRef

82.

Pinzon OW, Stoddard G, Drakos SG, Gilbert EM, Nativi JN, Budge D et al (2011) Impact of donor left ventricular hypertrophy on survival after heart transplant. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 11(12):2755–2761CrossRef

83.

Aziz S, Soine LA, Lewis SL, Kruse AP, Levy WC et al (1997) Donor left ventricular hypertrophy increases risk for early graft failure. Transpl Int 10(6):446–450PubMedCrossRef

84.

Kuppahally SS, Valantine HA, Weisshaar D, Parekh H, Hung YY, Haddad F et al (2007) Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 7(10):2388–2395CrossRef

85.

Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Kirk R et al (2010) The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report—2010. J Heart Lung Transplant 29(10):1089–1103PubMedCrossRef

86.

Dunn FG, Pringle SD (1987) Left ventricular hypertrophy and myocardial ischemia in systemic hypertension. Am J Cardiol 60(17):19–22CrossRef

87.

García Sáez D, Zych B, Sabashnikov A, Bowles CT, De Robertis F, Mohite PN et al (2014) Evaluation of the organ care system in heart transplantation with an adverse donor/recipient profile. Ann Thorac Surg 98(6):2099–2106PubMedCrossRef

88.

Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S et al (2010) The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 29(8):914–956PubMedCrossRef

89.

Movahed A, Reeves WC, Mehta PM, Gilliland MG, Mozingo SL, Jolly SR (1994) Norepinephrine-induced left ventricular dysfunction in anesthetized and conscious, sedated dogs. Int J Cardiol 45(1):23–33PubMedCrossRef

90.

D'Alessandro C, Golmard JL, Barreda E, Laali M, Makris R, Luyt CE et al (2011) Predictive risk factors for primary graft failure requiring temporary extra-corporeal membrane oxygenation support after cardiac transplantation in adults. Eur J Cardiothorac Surg 40(4):962–969PubMed

91.

Santise G, D'Ancona G, Falletta C, Pirone F, Sciacca S, Turrisi M et al (2009) Donor pharmacological hemodynamic support is associated with primary graft failure in human heart transplantation. Interact Cardiovasc Thorac Surg 9(3):476–479PubMedCrossRef

92.

Segovia J, Cosio MD, Barcelo JM, Bueno MG, Pavia PG, Burgos R et al (2011) RADIAL: a novel primary graft failure risk score in heart transplantation. J Heart Lung Transplant 30(6):644–651PubMedCrossRef

93.

McKeown DW, Bonser RS, Kellum JA (2012) Management of the heartbeating brain-dead organ donor. Br J Anaesth 108(suppl_1):i96–i107PubMedCrossRef

94.

Yoshioka T, Sugimoto H, Uenishi M, Sakamoto T, Sadamitsu D, Sakano T et al (1986) Prolonged hemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study. Neurosurgery. 18(5):565–567PubMedCrossRef

95.

Venkateswaran RV, Steeds RP, Quinn DW, Nightingale P, Wilson IC, Mascaro JG et al (2009) The haemodynamic effects of adjunctive hormone therapy in potential heart donors: a prospective randomized double-blind factorially designed controlled trial. Eur Heart J 30(14):1771–1780PubMedCrossRef

96.

Hong KN, Iribarne A, Worku B, Takayama H, Gelijns AC, Naka Y et al (2011) Who is the high-risk recipient? Predicting mortality after heart transplant using pretransplant donor and recipient risk factors. Ann Thorac Surg 92(2):520–527PubMedPubMedCentralCrossRef

97.

Young JB, Hauptman PJ, Naftel DC, Ewald G, Aaronson K, Dec GW et al (2001) Determinants of early graft failure following cardiac transplantation, a 10-year, multi-institutional, multivariable analysis. J Heart Lung Transplant 20(2):212PubMedCrossRef

98.

Truby LK, Takeda K, Topkara VK, Takayama H, Garan AR, Yuzefpolskaya M et al (2018) Risk of severe primary graft dysfunction in patients bridged to heart transplantation with continuous-flow left ventricular assist devices. J Heart Lung Transplant 37(12):1433–1442PubMedCrossRef

99.

Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL et al (2017) Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant 36(10):1080–1086PubMedCrossRef

100.

Foroutan F, Ross HJ (2019) Primary graft dysfunction: the devil is in the details. Transplantation. 103(2):229–230PubMedCrossRef

101.

Foroutan F, Alba AC, Guyatt G, Duero Posada J, Ng Fat Hing N, Arseneau E et al (2018) Predictors of 1-year mortality in heart transplant recipients: a systematic review and meta-analysis. Heart. 104(2):151–160PubMedCrossRef

102.

Taghavi S, Jayarajan SN, Wilson LM, Komaroff E, Testani JM, Mangi AA (2013) Cardiac transplantation can be safely performed using selected diabetic donors. J Thorac Cardiovasc Surg 146(2):442–447PubMedPubMedCentralCrossRef

103.

Singh TP, Almond CS, Semigran MJ, Piercey G, Gauvreau K (2012) Risk prediction for early in-hospital mortality following heart transplantation in the United States. Circ Heart Fail 5(2):259–266PubMedCrossRef

104.

Yeom SY, Hwang HY, Oh S-J, Cho H-J, Lee H-Y, Kim K-B (2013) Heart transplantation in the elderly patients: midterm results. Korean J Thorac Cardiovasc Surg 46(2):111–116PubMedPubMedCentralCrossRef

105.

Bull DA, Karwande SV, Hawkins JA, Neumayer LA, Taylor DO, Jones KW et al (1996) Long-term results of cardiac transplantation in patients older than sixty years. UTAH Cardiac Transplant Program. J Thorac Cardiovasc Surg 111(2):423–427 discussion 7-8PubMedCrossRef

106.

Tjang YS, van der Heijden GJ, Tenderich G, Korfer R, Grobbee DE (2008) Impact of recipient’s age on heart transplantation outcome. Ann Thorac Surg 85(6):2051–2055PubMedCrossRef

107.

Morales D, Williams E, John R (2010) Is resternotomy in cardiac surgery still a problem?☆. Interact Cardiovasc Thorac Surg 11(3):277–286PubMedCrossRef

108.

Kuralay E, Bolcal C, Cingoz F, Gunay C, Yildirim V, Kilic S et al (2004) Cardiac reoperation by Carpentier bicaval femoral venous cannula: GATA experience. Ann Thorac Surg 77(3):977–981 discussion 82PubMedCrossRef

109.

Still S, Shaikh AF, Qin H, Felius J, Jamil AK, Saracino G et al (2018) Reoperative sternotomy is associated with primary graft dysfunction following heart transplantation. Interact Cardiovasc Thorac Surg

110.

Awad M, Czer LS, Mirocha J, Ruzza A, Rafiei M, Reich H et al (2015) Prior sternotomy increases the mortality and morbidity of adult heart transplantation. Transplant Proc 47(2):485–497PubMedCrossRef

111.

Kansara P, Czer L, Awad M, Arabia F, Mirocha J, De Robertis M et al (2014) Heart transplantation with and without prior sternotomy: analysis of the United Network for Organ Sharing database. Transplant Proc 46(1):249–255PubMedCrossRef

112.

Santangeli P, Rame JE, Birati EY, Marchlinski FE (2017) Management of ventricular arrhythmias in patients with advanced heart failure. J Am Coll Cardiol 69(14):1842–1860PubMedCrossRef

113.

Macdonald P, Hackworthy R, Keogh A, Sivathasan C, Chang V, Spratt P (1991) The effect of chronic amiodarone therapy before transplantation on early cardiac allograft function. J Heart Lung Transplant 10(5 Pt 1):743–748 discussion 8-9PubMed

114.

Chelimsky-Fallick C, Middlekauff HR, Stevenson WG, Kobashigawa J, Saxon LA, Moriguchi J et al (1992) Amiodarone therapy does not compromise subsequent heart transplantation. J Am Coll Cardiol 20(7):1556–1561PubMedCrossRef

115.

Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA et al (2016) Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation. Drug Des Devel Ther 10:677–686PubMedPubMedCentral

116.

Wright M, Takeda K, Mauro C, Jennings D, Kurlansky P, Han J et al (2017) Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. J Heart Lung Transplant 36(11):1226–1233PubMedCrossRef

117.

Chin C, Feindel C, Cheng D (1999) Duration of preoperative amiodarone treatment may be associated with postoperative hospital mortality in patients undergoing heart transplantation. J Cardiothorac Vasc Anesth 13(5):562–566PubMedCrossRef

118.

Halazun KJ, Al-Mukhtar A, Aldouri A, Willis S, Ahmad N (2007) Warm ischemia in transplantation: search for a consensus definition. Transplant Proc 39(5):1329–1331PubMedCrossRef

119.

Squiers JJ, Saracino G, Chamogeorgakis T, MacHannaford JC, Rafael AE, Gonzalez-Stawinski GV et al (2017) Application of the International Society for Heart and Lung Transplantation (ISHLT) criteria for primary graft dysfunction after cardiac transplantation: outcomes from a high-volume centredagger. Eur J Cardiothorac Surg 51(2):263–270PubMed

120.

Banner NR, Thomas HL, Curnow E, Hussey JC, Rogers CA, Bonser RS (2008) The importance of cold and warm cardiac ischemia for survival after heart transplantation. Transplantation. 86(4):542–547PubMedCrossRef

121.

Wong G, Teixeira-Pinto A, Chapman JR, Craig JC, Pleass H, McDonald S et al (2017) The impact of total ischemic time, donor age and the pathway of donor death on graft outcomes after deceased donor kidney transplantation. Transplantation. 101(6):1152–1158PubMedCrossRef

122.

Salis S, Mazzanti VV, Merli G, Salvi L, Tedesco CC, Veglia F et al (2008) Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality after cardiac surgery. J Cardiothorac Vasc Anesth 22(6):814–822PubMedCrossRef

123.

Kirklin JW (1980) Open-heart surgery at the Mayo Clinic. The 25th anniversary. Mayo Clin Proc 55(5):339–341PubMed

124.

Anselmi A, Abbate A, Girola F, Nasso G, Biondi-Zoccai GG, Possati G et al (2004) Myocardial ischemia, stunning, inflammation, and apoptosis during cardiac surgery: a review of evidence. Eur J Cardiothorac Surg 25(3):304–311PubMedCrossRef

125.

Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD (2007) Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 116(22):2544–2552PubMedCrossRef

126.

Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD et al (2006) Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 34(6):1608–1616PubMedCrossRef

127.

Kuduvalli M, Oo AY, Newall N, Grayson AD, Jackson M, Desmond MJ et al (2005) Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery. Eur J Cardiothorac Surg 27(4):592–598PubMedCrossRef

128.

Reed RM, Netzer G, Hunsicker L, Mitchell BD, Rajagopal K, Scharf S et al (2014) Cardiac size and sex-matching in heart transplantation: size matters in matters of sex and the heart. JACC Heart Fail 2(1):73–83PubMedPubMedCentralCrossRef

129.

Smits JM, Vanhaecke J, Haverich A, de Vries E, Smith M, Rutgrink E et al (2003) Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant, 1997-1999. Clin Transpl:89–100

130.

Patel ND, Weiss ES, Nwakanma LU, Russell SD, Baumgartner WA, Shah AS et al (2008) Impact of donor-to-recipient weight ratio on survival after heart transplantation: analysis of the United Network for Organ Sharing Database. Circulation. 118(14 Suppl):S83–S88PubMedCrossRef

131.

Weiss ES, Allen JG, Patel ND, Russell SD, Baumgartner WA, Shah AS et al (2009) The impact of donor-recipient sex matching on survival after orthotopic heart transplantation: analysis of 18 000 transplants in the modern era. Circ Heart Fail 2(5):401–408PubMedCrossRef

132.

Stehlik J, Feldman DS, Brown RN, VanBakel AB, Russel SD, Ewald GA et al (2010) Interactions among donor characteristics influence post-transplant survival: a multi-institutional analysis. J Heart Lung Transplant 29(3):291–298PubMedCrossRef

133.

Jayarajan SN, Taghavi S, Komaroff E, Mangi AA (2013) Impact of low donor to recipient weight ratios on cardiac transplantation. J Thorac Cardiovasc Surg 146(6):1538–1543PubMedCrossRef

134.

Murphy K, Kransdorf EP, Wilansky S, Pajaro OE, Steidley DE (2016) Impact of size mismatch on heart transplant outcomes. J Heart Lung Transplant 35(4):S214–S2S5CrossRef

135.

Kertesz NJ, Gajarski RJ, Towbin JA, Geva T (1995) Effect of donor-recipient size mismatch on left ventricular remodeling after pediatric orthotopic heart transplantation. Am J Cardiol 76(16):1167–1172PubMedCrossRef

136.

Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 104(4):487–501PubMedCrossRef

137.

Cui X, Chang L, Li Y, Lv Q, Wang F, Lin Y et al (2018) Trivalent soluble TNF receptor, a potent TNF-alpha antagonist for the treatment collagen-induced arthritis. Sci Rep 8(1):7327PubMedPubMedCentralCrossRef

138.

Mukhopadhyay S, Hoidal JR, Mukherjee TK (2006) Role of TNFα in pulmonary pathophysiology. Respir Res 7(1):125PubMedPubMedCentralCrossRef

139.

Sack MN (2002) Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease. Pharmacol Ther 94(1):123–135PubMedCrossRef

140.

Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323(4):236–241PubMedCrossRef

141.

Birks EJ, Burton PB, Owen V, Mullen AJ, Hunt D, Banner NR et al (2000) Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation 102(19 Suppl 3):Iii352–Iii358PubMed

142.

Tatham KC, O'Dea KP, Romano R, Donaldson HE, Wakabayashi K, Patel BV et al (2018) Intravascular donor monocytes play a central role in lung transplant ischaemia-reperfusion injury. Thorax. 73(4):350–360PubMedCrossRef

143.

Schnickel GT, Ross DJ, Beygui R, Shefizadeh A, Laks H, Saggar R et al (2006) Modified reperfusion in clinical lung transplantation: the results of 100 consecutive cases. J Thorac Cardiovasc Surg 131(1):218–223PubMedCrossRef

144.

Venkateswaran RV, Dronavalli V, Lambert PA, Steeds RP, Wilson IC, Thompson RD et al (2009) The proinflammatory environment in potential heart and lung donors: prevalence and impact of donor management and hormonal therapy. Transplantation. 88(4):582–588PubMedCrossRef

145.

Braulio R, Sanches MD, Teixeira Junior AL, Costa PHN, Moreira MCV, Rocha MA et al (2016) Associated clinical and laboratory markers of donor on allograft function after heart transplant. Braz J Cardiovasc Surg 31(2):89–97PubMedPubMedCentral

146.

Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):a016295PubMedPubMedCentralCrossRef

147.

Fontes JA, Rose NR, Čiháková D (2015) The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 74(1):62–68PubMedPubMedCentralCrossRef

148.

Plenz G, Eschert H, Erren M, Wichter T, Böhm M, Flesch M et al (2002) The interleukin-6/interleukin-6-receptorsystem is activated in donor hearts. J Am Coll Cardiol 39(9):1508–1512PubMedCrossRef

149.

Moreno I, Vicente R, Ramos F, Vicente JL, Barbera M (2007) Determination of interleukin-6 in lung transplantation: association with primary graft dysfunction. Transplant Proc 39(7):2425–2426PubMedCrossRef

150.

Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML (1995) Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation. 92(7):1866–1875PubMedCrossRef

151.

Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH et al (1999) Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. 99(4):546–551PubMedCrossRef

152.

Jin M, Khan AI (2010) Procalcitonin: uses in the clinical laboratory for the diagnosis of sepsis. Lab Med 41(3):173–177CrossRef

153.

Sandkovsky U, Kalil AC, Florescu DF (2015) The use and value of procalcitonin in solid organ transplantation. Clin Transpl 29(8):689–696CrossRef

154.

Yu XY, Wang Y, Zhong H, Dou QL, Song YL, Wen H (2014) Diagnostic value of serum procalcitonin in solid organ transplant recipients: a systematic review and meta-analysis. Transplant Proc 46(1):26–32PubMedCrossRef

155.

Madershahian N, Wittwer T, Strauch J, Wippermann J, Rahmanian P, Franke UF et al (2008) Kinetic of procalcitonin in the early postoperative course following heart transplantation. J Card Surg 23(5):468–473PubMedCrossRef

156.

Wagner FD, Jonitz B, Potapov EV, Qedra N, Wegscheider K, Abraham K et al (2001) Procalcitonin, a donor-specific predictor of early graft failure-related mortality after heart transplantation. Circulation. 104(12 Suppl 1):I192–I196PubMedCrossRef

157.

van Ree RM, de Vries AP, Oterdoom LH, Seelen MA, Gansevoort RT, Schouten JP et al (2009) Plasma procalcitonin is an independent predictor of graft failure late after renal transplantation. Transplantation. 88(2):279–287PubMedCrossRef

158.

Eyraud D, Ben Ayed S, Tanguy ML, Vezinet C, Siksik JM, Bernard M et al (2008) Procalcitonin in liver transplantation: are high levels due to donors or recipients? Crit Care (London, England) 12(4):R85CrossRef

159.

Sammons C, Doligalski CT (2014) Utility of procalcitonin as a biomarker for rejection and differentiation of infectious complications in lung transplant recipients. Ann Pharmacother 48(1):116–122PubMedCrossRef

160.

Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G et al (2013) Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 11(1):55–59PubMedCrossRef

161.

Ucar FM, Acar B, Gul M, Ozeke O, Aydogdu S (2016) The association between platelet/lymphocyte ratio and coronary artery disease severity in asymptomatic low ejection fraction patients. Korean Circ J 46(6):821–826PubMedPubMedCentralCrossRef

162.

Huang WM, Cheng HM, Huang CJ, Guo CY, Lu DY, Lee CW et al (2017) Hemographic indices are associated with mortality in acute heart failure. Sci Rep 7(1):17828PubMedPubMedCentralCrossRef

163.

Yost G, Ibrahim K, Tatooles A, Bhat G (2017) Longitudinal neutrophil to lymphocyte ratio assessment after left ventricular assist device implantation. J Heart Lung Transplant 36(4):S349CrossRef

164.

Seropian IM, Romeo FJ, Pizarro R, Vulcano NO, Posatini RA, Marenchino RG et al (2018) Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictors of survival after heart transplantation. ESC Heart Fail 5(1):149–156PubMedCrossRef

165.

Hogendorf P, Suska A, Skulimowski A, Rut J, Grochowska M, Wencel A et al (2018) Neutrophil-lymphocyte ratio and creatinine reduction ratio predict good early graft function among adult cadaveric donor renal transplant recipients. Single institution series. Polski przeglad chirurgiczny 90(2):28–33PubMedCrossRef

166.

Yost G, Bhat G, Pappas P, Tatooles A (2018) The neutrophil to lymphocyte ratio in patients supported with extracorporeal membrane oxygenation. Perfusion. 267659118772455

167.

Sharma S, Jackson PG, Makan J (2004) Cardiac troponins. J Clin Pathol 57(10):1025–1026PubMedPubMedCentralCrossRef

168.

Dronavalli VB, Banner NR, Bonser RS (2010) Assessment of the potential heart donor: a role for biomarkers? J Am Coll Cardiol 56(5):352–361PubMedCrossRef

169.

Riou B, Dreux S, Roche S, Arthaud M, Goarin JP, Léger P et al (1995) Circulating cardiac troponin T in potential heart transplant donors. Circulation. 92(3):409–414PubMedCrossRef

170.

Potapov EV, Wagner FD, Loebe M, Ivanitskaia EA, Müller C, Sodian R et al (2003) Elevated donor cardiac troponin T and procalcitonin indicate two independent mechanisms of early graft failure after heart transplantation. Int J Cardiol 92(2):163–167PubMedCrossRef

171.

Vijay P, Scavo VA, Morelock RJ, Sharp TG, Brown JW (1998) Donor cardiac troponin T: a marker to predict heart transplant rejection. Ann Thorac Surg 66(6):1934–1939PubMedCrossRef

172.

Potapov EV, Ivanitskaia EA, Loebe M, Mückel M, Müller C, Sodian R et al (2001) Value of cardiac troponin I and T for selection of heart donors and as predictors of early graft failure. Transplantation. 71(10):1394–1400PubMedCrossRef

173.

Deibert E, Aiyagari V, Diringer MN (2000) Reversible left ventricular dysfunction associated with raised troponin I after subarachnoid haemorrhage does not preclude successful heart transplantation. Heart. 84(2):205–207PubMedPubMedCentralCrossRef

174.

Deibert E, Barzilai B, Braverman AC, Edwards DF, Aiyagari V, Dacey R et al (2003) Clinical significance of elevated troponin I levels in patients with nontraumatic subarachnoid hemorrhage. J Neurosurg 98(4):741–746PubMedCrossRef

175.

Boccheciampe N, Audibert G, Rangeard O, Charpentier C, Perrier JF, Lalot JM et al (2009) Serum troponin Ic values in organ donors are related to donor myocardial dysfunction but not to graft dysfunction or rejection in the recipients. Int J Cardiol 133(1):80–86PubMedCrossRef

176.

Khush KK, Menza RL, Babcock WD, Zaroff JG (2007) Donor cardiac troponin I levels do not predict recipient survival after cardiac transplantation. J Heart Lung Transplant 26(10):1048–1053PubMedCrossRef

177.

Madan S, Saeed O, Shin J, Sims D, Goldstein D, Pina I, et al. Donor troponin and survival after cardiac transplantation: an analysis of the United Network of Organ Sharing Registry. Circ Heart Fail. 2016;9(6)

178.

Schechter MA, Watson MJ, Feger BJ, Southerland KW, Mishra R, Dibernardo LR et al (2016) Elevated cardiac troponin I in preservation solution is associated with primary graft dysfunction. J Card Fail 22(2):158–162PubMedCrossRef

179.

Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F (2004) Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart. 90(3):297–303PubMedPubMedCentralCrossRef

180.

Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y et al (1996) Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension (Dallas, Tex : 1979) 28(6):988–994CrossRef

181.

Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Thanapiboonpol P, Nakyen S, Udompunturak S (2008) Correlation between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. J Card Fail 14(8):687–694PubMedCrossRef

182.

Giallauria F, Cirillo P, Lucci R, Pacileo M, De Lorenzo A, D’Agostino M et al (2008) Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: favourable effects of exercise training and predictive role of N-terminal pro-brain natriuretic peptide. Eur J Cardiovasc Prev Rehabil 15(1):113–118PubMedCrossRef

183.

de Lemos JA, Morrow DA (2007) Use of natriuretic peptides in clinical decision-making for patients with non–ST-elevation acute coronary syndromes. Am Heart J 153(4):450–453PubMedCrossRef

184.

Dronavalli VB, Ranasinghe AM, Venkateswaran RJ, James SR, McCabe CJ, Wilson IC et al (2010) N-terminal pro-brain-type natriuretic peptide: a biochemical surrogate of cardiac function in the potential heart donor. Eur J Cardiothorac Surg 38(2):181–186PubMedCrossRef

185.

Vorlat A, Conraads VM, Jorens PG, Aerts S, Van Gorp S, Vermeulen T et al (2012) Donor B-type natriuretic peptide predicts early cardiac performance after heart transplantation. J heart lung transplant 31(6):579–584PubMedCrossRef

186.

Aharinejad S, Andrukhova O, Gmeiner M, Thomas A, Aliabadi A, Zuckermann A et al (2009) Donor serum SMARCAL1 concentrations predict primary graft dysfunction in cardiac transplantation. Circulation. 120(11 Suppl):S198–S205PubMedCrossRef

187.

Jiang BH, Rue E, Wang GL, Roe R, Semenza GL (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271(30):17771–17778PubMedCrossRef

188.

Aharinejad S, Schafer R, Krenn K, Zuckermann A, Schneider B, Neumann F et al (2007) Donor myocardial HIF-1alpha is an independent predictor of cardiac allograft dysfunction: a 7-year prospective, exploratory study. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 7(8):2012–2019CrossRef

189.

Loor G, Schumacker PT (2008) Role of hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion. Cell Death Differ 15(4):686–690PubMedCrossRef

190.

Amaral N, Okonko DO (2015) Mitigation of myocardial ischemia-reperfusion injury via HIF-1alpha-frataxin signaling. Am J Physiol Heart Circ Physiol 309(5):H728–H730PubMedPubMedCentralCrossRef

191.

Giangreco N, Chen E, Zorn E, Restaino S, Colombo PC, Tatonetti N et al (2017) Abstract 19311: identification of novel primary graft dysfunction biomarkers using exosome proteomics. Circulation 136(Suppl 1):A19311–A1931A

192.

Fine B, Chen E, Lebreton G, Restaino S, Taupin J, Zorn E et al (2018) Pre-transplant serum exosome proteomics differentiates right and left ventricular primary graft dysfunction. J Heart Lung Transplant 37(4):S24CrossRef

193.

Wagner FM, Subbotina I, Deuse T, Marcsek P, Treede H, Kubik M et al (2013) Additional intraoperative blood cardioplegia to improve donor heart ischemic tolerance—a single center prospective cohort study. Thorac Cardiovasc Surg 61(S 01):OP127CrossRef

194.

Cerny S, Pavel P, Pirk J, Hola I, Brezina A, Sedlacek J et al (2002) Donor myocardial protection using secondary blood cardioplegia during heart transplantation: prospective randomized study in 100 patients. J Heart Lung Transplant 21(1):61–62CrossRef

195.

Morcos K, Singh S, De Das S, AlHaideri H, Hegazy Y, Dalzell J et al (2018) Novel technique to reduce warm ischemic time during cardiac implantation. J Heart Lung Transplant 37(4):S425CrossRef

196.

Habertheuer A, Kocher A, Laufer G, Andreas M, Szeto WY, Petzelbauer P et al (2014) Cardioprotection: a review of current practice in global ischemia and future translational perspective. BioMed Res Int 2014:325725PubMedPubMedCentralCrossRef

197.

Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Soffker G et al (2007) Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 35(12):2732–2739PubMed

198.

Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 297(17):1883–1891PubMedCrossRef

199.

Weis F, Beiras-Fernandez A, Kaczmarek I, Sodian R, Kur F, Weis M et al (2009) Levosimendan: a new therapeutic option in the treatment of primary graft dysfunction after heart transplantation. J Heart Lung Transplant 28(5):501–504PubMedCrossRef

200.

Beiras-Fernandez A, Kur F, Kaczmarek I, Frisch P, Weis M, Reichart B et al (2011) Levosimendan for primary graft failure after heart transplantation: a 3-year follow-up. Transplant Proc 43(6):2260–2262PubMedCrossRef

201.

Sundberg S, Antila S, Scheinin H, Hayha M, Virtanen M, Lehtonen L (1998) Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int J Clin Pharmacol Ther 36(12):629–635PubMed

202.

Du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A (2008) A role for the RISK pathway and KATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol 154(1):41–50PubMedPubMedCentralCrossRef

203.

Papp JG, Pollesello P, Varró AF, Végh ÁS (2006) Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther 11(2):129–135PubMedCrossRef

204.

Cammarata GAAM, Weil MH, Sun S, Huang L, Fang X, Tang W (2006) Levosimendan improves cardiopulmonary resuscitation and survival by KATPChannel activation. J Am Coll Cardiol 47(5):1083–1085PubMedCrossRef

205.

Hönisch A, Theuring N, Ebner B, Wagner C, Strasser RH, Weinbrenner C (2010) Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res Cardiol 105(2):155–167PubMedCrossRef

206.

Hasslacher J, Bijuklic K, Bertocchi C, Kountchev J, Bellmann R, Dunzendorfer S et al (2011) Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Critical Care (London, England) 15(4):R166-RCrossRef

207.

Nguyen TC, Kiss JE, Goldman JR, Carcillo JA (2012) The role of plasmapheresis in critical illness. Crit Care Clin 28(3):453–viiPubMedPubMedCentralCrossRef

208.

Rydberg L (2001) ABO-incompatibility in solid organ transplantation. Transfusion medicine (Oxford, England) 11(4):325–342CrossRef

209.

Wang SS, Chou NK, Ko WJ, Chi NH, Hung SC, Hsu RB et al (2006) Effect of plasmapheresis for acute humoral rejection after heart transplantation. Transplant Proc 38(10):3692–3694PubMedCrossRef

210.

Ince V, Aydin C, Otan E, Karabulut K, Koc S, Kayaalp C et al (2013) Comparison of plasmapheresis and molecular adsorbent recirculating system efficacy in graft failure after living donor liver transplantation. Transplant Proc 45(3):971–973PubMedCrossRef

211.

Mandal AK, King KE, Humphreys SL, Maley WR, Burdick JF, Klein AS (2000) Plasmapheresis: an effective therapy for primary allograft nonfunction after liver transplantation. Transplantation. 70(1):216–220PubMed

212.

Chou HW, Chi NH, Lin MH, Chou NK, Tsao CI, Yu HY et al (2012) Steroid pulse therapy combined with plasmapheresis for clinically compromised patients after heart transplantation. Transplant Proc 44(4):900–902PubMedCrossRef

213.

Chang DH, Kittleson M, Patel J, Aintablian T, Levine R, Geft D et al (2017) (373) - Treatment of primary graft dysfunction with plasmapheresis improves outcome. J Heart Lung Transplant 36(4, Supplement):S147CrossRef

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Primary graft dysfunction after heart transplantation: a thorn amongst the roses

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies

Right ventricular function after cardiac surgery: the diagnostic and prognostic role of echocardiography

Targeting transcriptional machinery to inhibit enhancer-driven gene expression in heart failure

Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials